Incanthera Company

Incanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific matrix metalloprotease enzyme. The company was incorporated in 2010 and is based in Liverpool, United Kingdom.

Headquarters: Liverpool, Liverpool, United Kingdom
Estimated Revenue: £780 000 - £7 800 000
Founded Date: 2010
Industry: PharmTech